azd-6244 and Cachexia

azd-6244 has been researched along with Cachexia* in 3 studies

Trials

1 trial(s) available for azd-6244 and Cachexia

ArticleYear
Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma.
    British journal of cancer, 2012, May-08, Volume: 106, Issue:10

    Cancer cachexia is characterised by skeletal muscle wasting; however, potential for muscle anabolism in patients with advanced cancer is unproven.. Quantitative analysis of computed tomography images for loss/gain of muscle in cholangiocarcinoma patients receiving selumetinib (AZD6244; ARRY-142886) in a Phase II study, compared with a separate standard therapy group. Selumetinib is an inhibitor of mitogen-activated protein/extracellular signal-regulated kinase and of interleukin-6 secretion, a putative mediator of muscle wasting.. Overall, 84.2% of patients gained muscle after initiating selumetinib; mean overall gain of total lumbar muscle cross-sectional area was 13.6 cm(2)/100 days (∼2.3 kg on a whole-body basis). Cholangiocarcinoma patients who began standard treatment were markedly catabolic, with overall muscle loss of -7.3 cm(2)/100 days (∼1.2 kg) and by contrast only 16.7% of these patients gained muscle.. Our findings suggest that selumetinib promotes muscle gain in patients with cholangiocarcinoma. Specific mechanisms and relevance for cachexia therapy remain to be investigated.

    Topics: Adult; Aged; Benzimidazoles; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cachexia; Cholangiocarcinoma; Female; Humans; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Muscle, Skeletal; Protein Kinase Inhibitors

2012

Other Studies

2 other study(ies) available for azd-6244 and Cachexia

ArticleYear
Selumetinib Attenuates Skeletal Muscle Wasting in Murine Cachexia Model through ERK Inhibition and AKT Activation.
    Molecular cancer therapeutics, 2017, Volume: 16, Issue:2

    Cancer cachexia is a multifactorial syndrome affecting the skeletal muscle. Previous clinical trials showed that treatment with MEK inhibitor selumetinib resulted in skeletal muscle anabolism. However, it is conflicting that MAPK/ERK pathway controls the mass of the skeletal muscle. The current study investigated the therapeutic effect and mechanisms of selumetinib in amelioration of cancer cachexia. The classical cancer cachexia model was established via transplantation of CT26 colon adenocarcinoma cells into BALB/c mice. The effect of selumetinib on body weight, tumor growth, skeletal muscle, food intake, serum proinflammatory cytokines, E3 ligases, and MEK/ERK-related pathways was analyzed. Two independent experiments showed that 30 mg/kg/d selumetinib prevented the loss of body weight in murine cachexia mice. Muscle wasting was attenuated and the expression of E3 ligases, MuRF1 and Fbx32, was inhibited following selumetinib treatment of the gastrocnemius muscle. Furthermore, selumetinib efficiently reduced tumor burden without influencing the cancer cell proliferation, cumulative food intake, and serum cytokines. These results indicated that the role of selumetinib in attenuating muscle wasting was independent of cancer burden. Detailed analysis of the mechanism revealed AKT and mTOR were activated, while ERK, FoxO3a, and GSK3β were inhibited in the selumetinib -treated cachexia group. These indicated that selumetinib effectively prevented skeletal muscle wasting in cancer cachexia model through ERK inhibition and AKT activation in gastrocnemius muscle via cross-inhibition. The study not only elucidated the mechanism of MEK/ERK inhibition in skeletal muscle anabolism, but also validated selumetinib therapy as an effective intervention against cancer cachexia. Mol Cancer Ther; 16(2); 334-43. ©2016 AACR.

    Topics: Animals; Atrophy; Benzimidazoles; Biomarkers; Body Weight; Cachexia; Cell Line, Tumor; Colonic Neoplasms; Cytokines; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Humans; Inflammation Mediators; Mice; Models, Biological; Muscle, Skeletal; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Tumor Burden; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays

2017
Mitogen-Activated Protein Kinases Inhibitors: Potential Therapeutic Agents for Cancer Cachexia.
    Molecular cancer therapeutics, 2017, Volume: 16, Issue:2

    Topics: Benzimidazoles; Cachexia; Cell Line, Tumor; Enzyme Activation; Humans; Mitogen-Activated Protein Kinases; Neoplasms; Protein Kinase Inhibitors

2017